The National Science Foundation (NSF) awarded a $274,966 Project Grant to Remedium Bio Inc., a for-profit organization, under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant supports the development of an adjustable gene therapy platform technology that will enable the use of genetic therapeutics beyond rare diseases, tackling large unmet clinical needs such as diabetes, osteoarthritis, and autoimmune diseases. The project aims to develop a dose-adjustable gene therapy mechanism that can be used to up- or down-regulate a gene therapy dose following initial administration, addressing a key limitation of current gene therapy approaches. This technology has significant commercial value while also having the potential to greatly reduce societal medical costs associated with current treatment approaches.
Generated 4/30/24, 1:55 AM